Paul R. Fonteyne
Directeur/Membre du Conseil chez AMYLYX PHARMACEUTICALS, INC.
Fortune : 279 184 $ au 30/04/2024
Profil
Paul R.
Fonteyne is the founder of Thyron Pharmaceuticals, Inc. (founded in 2021) and holds the title of Chief Executive Officer.
He is also the founder of Allyx Therapeutics, Inc. Mr. Fonteyne's current job(s) include Chairman at DalCor Pharmaceuticals Canada, Inc. (since 2019), Independent Director at Ypsomed Holding AG (since 2018), Director at Ypsomed AG, Independent Director at Amylyx Pharmaceuticals, Inc. (since 2021), Independent Director at Apnimed, Inc. (since 2023), Director at DalCor Pharma UK Ltd., Director at Revelar Biotherapeutics, Inc., and Independent Director at Apellis Pharmaceuticals, Inc. (since 2020).
Mr. Fonteyne's former job(s) include Chairman-CEOs Against Cancer at American Cancer Society, Inc., President & Chief Executive Officer at Boehringer Ingelheim Pharmaceuticals, Inc. (2012-2018), Chairman, President, Chief Executive Officer & MD at Boehringer Ingelheim Corp.
(2010-2019), Chairman at National Pharmaceutical Council, Director at Gelesis, Inc. (2018-2022), Director at Pharmaceutical Research & Manufacturers of America, Independent Director at AMAG Pharmaceuticals, Inc. (2019-2020), Independent Director at resTORbio, Inc. (2017-2020), Independent Director at Covetrus, Inc. (2021-2022), Independent Director at Gelesis Holdings, Inc. (2022-2023), Vice President-Sales at Merck & Co., Inc., Senior VP-Prescription Medicines Marketing at Boehringer Ingelheim GmbH (2009-2011), and President at Boehringer Ingelheim Animal Health USA, Inc. (2018-2019).
Mr. Fonteyne's education includes an MBA from Carnegie Mellon University (1987) and a graduate degree from Université Libre de Bruxelles.
Mr. Fonteyne is also the founder of Allyx Therapeutics, Inc...
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2024 | 5 676 ( 0,00% ) | 272 051 $ | 30/04/2024 | |
| 12/04/2024 | 3 947 ( 0,01% ) | 7 026 $ | 30/04/2024 | |
GELESIS HOLDINGS, INC.
0,07% | 17/03/2023 | 53 832 ( 0,07% ) | 108 $ | 31/12/2023 |
Postes actifs de Paul R. Fonteyne
| Sociétés | Poste | Début |
|---|---|---|
| YPSOMED HOLDING AG | Directeur/Membre du Conseil | 01/01/2018 |
| APELLIS PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 06/04/2020 |
| AMYLYX PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 29/03/2021 |
Ypsomed AG
 Ypsomed AG Medical SpecialtiesHealth Technology Part of Ypsomed Holding AG, Ypsomed AG is a Swiss company that manufactures injection and infusion systems for self-medication and renowned diabetes. The company is based in Burgdorf, Switzerland. | Directeur/Membre du Conseil | - |
| Thyron Pharmaceuticals, Inc. | Directeur Général | 01/04/2021 |
DalCor Pharma UK Ltd.
 DalCor Pharma UK Ltd. BiotechnologyHealth Technology Founded in 2015, DalCor Pharma UK Ltd. is a subsidiary of DalCor Pharmaceuticals Canada, Inc. The company is based in Leatherhead, UK. The British company engages in research and experimental development on biotechnology. | Directeur/Membre du Conseil | 27/02/2019 |
Revelar Biotherapeutics, Inc.
 Revelar Biotherapeutics, Inc. BiotechnologyHealth Technology Revelar Biotherapeutics is a biopharmaceutical company based in Bethesda, MD. Revelar Biotherapeutics, Inc. focuses on developing and commercializing breakthrough therapeutic antibody products to address critical unmet patient needs, particularly in the field of COVID-19 and other therapeutic areas. The company's management team has extensive expertise in clinical development, regulatory affairs, business development, and operations with leading pharmaceutical companies. Revelar was spun out of Twist Bioscience in November 2021 and has the ability to leverage Twist Biopharma's antibody discovery and optimization platform to license additional antibodies for non-COVID targets. The company's therapeutic areas of interest include oncology and infectious diseases. Revelar aims to combine its clinical development and commercialization capabilities with Twist's innovative technology platform and industry and academia collaborations to accelerate the discovery and delivery of transformative antibody therapeutics to meet patients' unmet needs. Revelar was founded by Kevin P. Malobisky, and the CEO is Glenn Marina. | Directeur/Membre du Conseil | - |
Allyx Therapeutics, Inc.
 Allyx Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Allyx Therapeutics is an American clinical-stage biotechnology company founded in 2019 by a group of experienced biopharma industry executives, venture capitalists, and scientific experts. The company is based in an undisclosed location and aims to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases. Its lead compound, alx-001, is a first-in-class oral therapy with a unique mechanism of action at mglur5 currently in clinical development in Alzheimer's disease. The company is developing an oral drug that demonstrates reversal of learning and memory deficits due to Alzheimer's disease. The company was founded by Timothy Siegert, Stephen M. Bloch, Paul R. Fonteyne, and Stephen M. Bloch has been the CEO since incorporation. | Fondateur | - |
DalCor Pharmaceuticals Canada, Inc.
 DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | Président | 27/02/2019 |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Anciens postes connus de Paul R. Fonteyne
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Paul R. Fonteyne
| Carnegie Mellon University | Masters Business Admin |
| Université Libre de Bruxelles | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| APELLIS PHARMACEUTICALS, INC. | Health Technology |
| YPSOMED HOLDING AG | Health Technology |
| AMYLYX PHARMACEUTICALS, INC. | Health Technology |
| GELESIS HOLDINGS, INC. | Health Technology |
| Entreprise privées | 18 |
|---|---|
Boehringer Ingelheim GmbH
 Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Health Technology |
Gelesis, Inc.
 Gelesis, Inc. BiotechnologyHealth Technology Gelesis, Inc. operates as a consumer-centered biotherapeutics company, which engages in the development of novel therapies to induce weight loss and metabolic disorders. Its commercial product portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease /Non-alcoholic Steatohepatitis, and Functional Constipation. The company was founded by Yishai Zohar in 2006 and is headquartered in Boston, MA. | Health Technology |
American Cancer Society, Inc.
 American Cancer Society, Inc. Miscellaneous Commercial ServicesCommercial Services American Cancer Society, Inc. provides information on cancer occurrence, survival, prevention, early detection, and treatment. The non-profit company is based in Kennesaw, GA and has subsidiaries in the United States. The company's SHES department is an intramural research program with world-renowned epidemiologists and health scientists. The company was founded in 1913 by Candy Arrington. Karen E. Knudsen has been the CEO of the company since 2021. | Commercial Services |
Boehringer Ingelheim Pharmaceuticals, Inc.
 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Health Technology |
Boehringer Ingelheim Corp.
 Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Health Technology |
Boehringer Ingelheim Animal Health USA, Inc.
 Boehringer Ingelheim Animal Health USA, Inc. BiotechnologyHealth Technology Boehringer Ingelheim Animal Health USA, Inc. manufactures biological vaccines for animals. The firm specializes in pharmaceuticals for cattle, equine, pet, and swine. The company was founded by Albrecht Boehringer in 1885 and is headquartered in Duluth, GA. | Health Technology |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Health Technology |
National Pharmaceutical Council
 National Pharmaceutical Council Miscellaneous Commercial ServicesCommercial Services The National Pharmaceutical Council operates as a not for profit organization. It specializes in research development, information dissemination, education, and communication of information to patients. The company was founded in 1953 and is headquartered in Washington, DC. | Commercial Services |
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
Ypsomed AG
Ypsomed AG Medical SpecialtiesHealth Technology Part of Ypsomed Holding AG, Ypsomed AG is a Swiss company that manufactures injection and infusion systems for self-medication and renowned diabetes. The company is based in Burgdorf, Switzerland. | Health Technology |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | Health Technology |
resTORbio, Inc.
 resTORbio, Inc. BiotechnologyHealth Technology resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA. | Health Technology |
Covetrus, Inc.
 Covetrus, Inc. Packaged SoftwareTechnology Services Covetrus, Inc. engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships and successful financial outcomes for veterinary professionals. The firm geographically operates through the segments: North America, Europe and Asia Pacific (APAC) & Emerging Markets. The company was founded by Benjamin J. Shaw in April 2018 and is headquartered in Portland, ME. | Technology Services |
Apnimed, Inc.
 Apnimed, Inc. BiotechnologyHealth Technology Apnimed, Inc. operates as a clinical-stage company. It discovers novel pharmaceutical therapies for sleep apnea and related disorders. The company was founded by Lawrence G. Miller and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA. | Health Technology |
DalCor Pharma UK Ltd.
DalCor Pharma UK Ltd. BiotechnologyHealth Technology Founded in 2015, DalCor Pharma UK Ltd. is a subsidiary of DalCor Pharmaceuticals Canada, Inc. The company is based in Leatherhead, UK. The British company engages in research and experimental development on biotechnology. | Health Technology |
Allyx Therapeutics, Inc.
Allyx Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Allyx Therapeutics is an American clinical-stage biotechnology company founded in 2019 by a group of experienced biopharma industry executives, venture capitalists, and scientific experts. The company is based in an undisclosed location and aims to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases. Its lead compound, alx-001, is a first-in-class oral therapy with a unique mechanism of action at mglur5 currently in clinical development in Alzheimer's disease. The company is developing an oral drug that demonstrates reversal of learning and memory deficits due to Alzheimer's disease. The company was founded by Timothy Siegert, Stephen M. Bloch, Paul R. Fonteyne, and Stephen M. Bloch has been the CEO since incorporation. | Commercial Services |
Revelar Biotherapeutics, Inc.
Revelar Biotherapeutics, Inc. BiotechnologyHealth Technology Revelar Biotherapeutics is a biopharmaceutical company based in Bethesda, MD. Revelar Biotherapeutics, Inc. focuses on developing and commercializing breakthrough therapeutic antibody products to address critical unmet patient needs, particularly in the field of COVID-19 and other therapeutic areas. The company's management team has extensive expertise in clinical development, regulatory affairs, business development, and operations with leading pharmaceutical companies. Revelar was spun out of Twist Bioscience in November 2021 and has the ability to leverage Twist Biopharma's antibody discovery and optimization platform to license additional antibodies for non-COVID targets. The company's therapeutic areas of interest include oncology and infectious diseases. Revelar aims to combine its clinical development and commercialization capabilities with Twist's innovative technology platform and industry and academia collaborations to accelerate the discovery and delivery of transformative antibody therapeutics to meet patients' unmet needs. Revelar was founded by Kevin P. Malobisky, and the CEO is Glenn Marina. | Health Technology |
| Thyron Pharmaceuticals, Inc. |
